Molecular Targeting in West Chester is a biotechnology company specializing in the development of diagnostic and therapeutic molecules for cancer and cardiovascular diseases. Their lead product candidates, PSVue and Tc-99m Duramycin, aim to address critical medical needs in these areas.
In addition to their focus on molecular targeting, MTTI is expanding into the research reagents business, offering a diverse portfolio of products tailored to meet the demands of cutting-edge academic researchers, particularly in the field of fluorescence-based technologies.
Generated from their website's infomation